Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05933980CT.gov Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04483219CT.gov Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. | — | Unknown | — | — | — |
NCT04030260CT.gov Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marinesco-Sjogren Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Regorafenib (this asset) | Sun Yat-sen University | P2 | CCC · 53 |
| Irinotecan | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Nivolumab | Pfizer | P2 | B |
| Ipilimumab | Pfizer | P2 | B |
| Binimetinib | Pfizer | P2 | B |
| Celecoxib | Sun Yat-sen University | P2 | CCC |
| rp3 | Replimune, Inc. | P2 | CCC |
+12 more in the Marinesco-Sjogren Syndrome cohort
Other indications for Regorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 73 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
| Colorectal Adenocarcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Regorafenib in Marinesco-Sjogren Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/regorafenib-marinesco-sjogren-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →